#Merck

@jqph5mv752.bsky.social

1 hour ago

Safe-Guard Suspension Cattle & Sheep Dewormer

Safe-Guard Suspension Cattle & Sheep Dewormer #Sheep #Merck #OralDrench #Fenbendazole #SafeGuard #Suspension

Millie Hoe Science Journalist

@milliehoe.bsky.social

4 days ago

Merck identifies redundancies in NC as vaccine sales plummet The company announced layoffs at its Durham facilities as Gardasil sales fail to meet expectations.

Merck make 150+ redundancies as HPV vaccine sales plummet. The company announced layoffs at its Durham, North Carolina facilities as Gardasil sales fail to meet expectations.

Read my full article below:
#news #merck #vaccine

www.bioprocessintl.com/global-marke...

Thiard News@F4F

@newsen.bsky.social

5 days ago

Exploring the Growth Potential of the Neuroendocrine Carcinoma Market: Innovations in Treatment and Rising Demand The neuroendocrine carcinoma market is set for substantial growth due to increased disease incidence and advances in targeted therapies, enhancing treatment options.

Exploring the Growth Potential of the Neuroendocrine Carcinoma Market: Innovations in Treatment and Rising Demand #None #Boehringer_Ingelheim #Immunotherapy #Merck

Novaknown

@novaknown.bsky.social

5 days ago

mRNA Cancer Vaccines: Why 2026 Readouts Matter for Oncology A 49% lower risk of melanoma coming back after surgery sounds like hype copy, but it’s a real number from Moderna and Merck’s individualized mRNA vaccine plus Keytruda combo at 5‑year follow‑up. That’s what mRNA cancer vaccines quietly did in a Phase 2b trial while Reddit argued about “curing cancer.” 2026 is when this stops being a handful of glamorous proofs‑of‑concept and becomes a practical question: can we actually run this at scale, pay for it, and plug it into messy real‑world oncology?

49% fewer melanoma recurrences at 5 years—Moderna/Merck’s mRNA vaccine + Keytruda worked. 2026 readouts will tell if this can scale, be paid for, and actually reach patients. #Moderna #Merck #Keytruda

@pharmalot.bsky.social

1 week ago

Pharmalittle: We're reading about Trump's MFN deals, 340B program controversies, and much more The most-favored nation drug pricing deals the Trump administration reached with 16 drugmakers end after three years in some cases, according to SEC filings

Pharmalot.. Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more news.. statnews.com/pharmalot/20... #pharma #medicines #prices #Trump #Europe #340B #hospitals #pharmacies #GLP1 #Merck #migraines

@pharmalot.bsky.social

2 weeks ago

Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Up and Down the Ladder: Job Changes.. the latest comings and goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #Merck #Roche